New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode

European Journal of Medicinal Chemistry

Volumn 96, Issue , 2015, Pages 318-329

  Rey Carrizo, Matias ^a   Gazzarrini, Sabrina ^b   Llabrés, Salomé ^a   Frigolé Vivas, Marta ^a   Juárez Jiménez, Jordi ^a   Font Bardia, Mercè ^a   Naesens, Lieve ^c   Moroni, Anna ^b   Luque, F Javier ^a   Vázquez, Santiago ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Amantadine; Influenza A; M2 channel; Molecular dynamics; Polycyclic amines; V27A mutant

Indexed keywords

13 AZAHEXACYCLO[8.5.2. 14,7 .0 2,9 .0 3,8 .0 11,15]OCTADECA 5,16 DIENE 12,14,18 TRIONE; 14 AMIDINO 14 AZAHEPTACYCLO[8.6.1.0 2,5 .0 3,11 0 4,9 .0 6,17 .0 12,16]HEPTADEC 7 ENE,HYDROCHLORIDE; 14 AMIDINO 14 AZAHEPTACYCLO[8.6.1.0 2,5 .0 3,11 0 4,9 .0 6,17 .0 12,16]HEPTADECANE HYDROCHLORIDE; 14 AZAHEPTACYCLO[8.6.1.0 2,5 .0 3,11 0 4,9 .0 6,17 .0 12,16]HEPTADEC 7 ENE 13,15 DIONE; 14 AZAHEPTACYCLO[8.6.1.0 2,5 .0 3,11 0 4,9 .0 6,17 .0 12,16]HEPTADEC 7 ENE,HYDROCHLORIDE; 14 AZAHEPTACYCLO[8.6.1.0 2,5 .0 3,11 0 4,9 .0 6,17 .0 12,16]HEPTADECANE,HYDROCHLORIDE; 4,5,6,7 TETRACHLORO 18,18 DIMETHOXY 13 AZAHEXACYCLO[8.5.2.14,7.0 2,9 .0 3,8 .0 11,15]OCTADECA 5,16 DIENE 12,14 DIONE; 5 AMIDINO 5 AZAPENTACYCLO [6.4.0.0 2,10 .0 3,7 .0 9,11]DODECANE HYDROCHLORIDE; 5 AZAPENTACYCLO [6.4.0.0 2,10 .0 3,7 .0 9,11]DODECANE HYDROCHLORIDE; 5 AZAPENTACYCLO[6.4.0.0 2,1 0.0 3,7 .0 9,11]DODECANE 4,6 DIONE; ALKANE DERIVATIVE; AMANTADINE; ANTIVIRUS AGENT; INFLUENZA A M2 POLYPEPTIDE; INFLUENZA A V27A PROTEIN; PROTEIN INHIBITOR; RIMANTADINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; POLYCYCLIC HYDROCARBON;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DECHLORINATION; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HYDROGENATION; HYDROLYSIS; HYDROPHOBICITY; IC50; INFLUENZA VIRUS A; MDCK CELL LINE; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; OOCYTE; STEREOISOMERISM; VIRUS STRAIN; XENOPUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL CULTURE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DOSE RESPONSE; DRUG EFFECTS; GENETICS; INFLUENZA A VIRUS; MICROBIAL SENSITIVITY TEST; MUTATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELL SURVIVAL; CELLS, CULTURED; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLUENZA A VIRUS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; POLYCYCLIC COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL MATRIX PROTEINS;

EID: 84928042879     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.04.030     Document Type: Article

References (61)

1. N.-A.M. Molinari, I.R. Ortega-Sanchez, M.L. Messonnier, W.W. Thompson, P.M. Wortley, E. Weintraub, C.B. Bridges, The annual impact of seasonal influenza in the US: measuring disease burden and costs, Vaccine 25 (2007) 5086-5096.
2. A.J. Hay, V. Gregory, A.R. Douglas, Y.P. Lin, The evolution of human influenza viruses, Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356 (2001) 1861-1870.
3. A.H. Reid, J.K. Taubenberger, T.G. Fanning, The 1918 Spanish influenza: integrating history and biology, Microbes Infect. 3 (2001) 81-87.
4. J.K. Taubenberger, D.M. Morens, 1918 Influenza: the mother of all pandemics, Emerg. Infect. Dis. 12 (2006) 15-22.
5. G. Neumann, T. Noda, Y. Kawaoka, Emergence and pandemic potential of swine-origin H1N1 influenza virus, Nature 459 (2009) 931-939.
6. J. Cohen, M. Enserink, After delays, WHO agrees: the 2009 pandemic has begun, Science 324 (2009) 1496-1497.
7. M. Michaelis, H.W. Doerr, J. Cinatl, Novel swine-origin influenza A virus in humans: another pandemic knocking at the door, Med. Microbiol. Immunol. 198 (2009) 175-183.
8. F.S. Dawood, A.D. Iuliano, C. Reed, M.I. Meltzer, D.K. Shay, P.-Y. Cheng, D. Bandaranayake, R.F. Breiman, W.A. Brooks, P. Buchy, D.R. Feikin, K.B. Fowler, A. Gordon, N.T. Hien, P. Horby, Q.S. Huang, M.A. Katz, A. Krishnan, R. Lal, J.M. Montgomery, K. Mølbak, R. Pebody, A.M. Presanis, H. Razuri, A. Steens, Y.O. Tinoco, J. Wallinga, H. Yu, S. Vong, J. Bresee, M.-A. Widdowson, Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study, Lancet Infect. Dis. 12 (2012) 687-695.
9. A. Abdel-Ghafar, T. Chotpitayasunondh, G. Zhancheng, F. Hayden, N. Hien, M. de Jong, A. Naghdaliyev, J. Peiris, N. Shindo, S. Soeroso, T. Uyeki, Update on avian influenza A (H5N1) virus infection in humans, N. Engl. J. Med. 358 (2008) 261-273.
10. H. Yu, B.J. Cowling, L. Feng, E.H.Y. Lau, Q. Liao, T.K. Tsang, Z. Peng, P. Wu, F. Liu, V.J. Fang, H. Zhang, M. Li, L. Zeng, Z. Xu, Z. Li, H. Luo, Q. Li, Z. Feng, B. Cao, W. Yang, J.T. Wu, Y. Wang, G.M. Leung, Human infection with avian influenza A H7N9 virus: an assessment of clinical severity, Lancet 382 (2013) 138-145.
11. S.M.-Y. Lee, H.-L. Yen, Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection, Antivir. Res. 96 (2012) 391-404.
12. E. Vanderlinden, L. Naesens, Emerging antiviral strategies to interfere with influenza virus entry, Med. Res. Rev. 34 (2014) 301-339.
13. R.A. Bright, D.K. Shay, B. Shu, N.J. Cox, A.I. Klimov, Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States, JAMA 295 (2006) 891-894.
14. F.G. Hayden, M.D. de Jong, Emerging influenza antiviral resistance threats, J. Infect. Dis. 203 (2011) 6-10.
15. A.E. Fiore, A.M. Fry, D.K. Shay, L.V. Gubareva, J.S. Bresee, T.M. Uyeki, Antiviral agents for the treatment and chemoprophylaxis of influenza e recommendations of the Advisory Committee on immunization Practices (ACIP), MMWR Recomm. Rep. 60 (2011) 1-28.
16. A. Moscona, Global transmission of oseltamivir-resistant influenza, N. Engl. J. Med. 360 (2009) 953-956.
17. M.M. Baz, Y. Abed, J. Papenburg, X. Bouhy, M.-E. Hamelin, G. Boivin, Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis, N. Engl. J. Med. 361 (2009) 2296-2297.
18. T.G. Sheu, A.M. Fry, R.J. Garten, V.M. Deyde, T. Shwe, L. Bullion, P.J. Peebles, Y. Li, A.I. Klimov, L.V. Gubareva, Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010, J. Infect. Dis. 203 (2011) 13-17.
19. L.H. Pinto, R.A. Lamb, The M2 proton channels of influenza A and B viruses, J. Biol. Chem. 281 (2006) 8997-9000.
20. L.H. Pinto, L.J. Holsinger, R.A. Lamb, Influenza virus M2 protein has ion channel activity, Cell 69 (1992) 517-528.
21. K. Takeuchi, R.A. Lamb, Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport, J. Virol. 68 (1994) 911-919.
22. S. Grambas, A.J. Hay, Maturation of influenza A virus hemagglutinin-estimates of the pH encountered during transport and its regulation by the M2 protein, Virology 190 (1992) 11-18.
23. V. Balannik, V. Carnevale, G. Fiorin, B.G. Levine, R.A. Lamb, M.L. Klein, W.F. Degrado, L.H. Pinto, Functional studies and modeling of pore-lining residue mutants of the influenza A virus M2 ion channel, Biochemistry 49 (2010) 696-708.
24. H. Suzuki, R. Saito, H. Masuda, H. Oshitani, M. Sato, I. Sato, Emergence of amantadine-resistant influenza A viruses: epidemiological study, J. Infect. Chemother. 9 (2003) 195-200.
25. Y. Furuse, A. Suzuki, H. Oshitani, Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance, Antimicrob. Agents Chemother. 53 (2009) 4457-4463.
26. R.A. Bright, M. Medina, X. Xu, G. Perez-Oronoz, T.R. Wallis, X.M. Davis, L. Povinelli, N.J. Cox, A.I. Klimov, Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern, Lancet 366 (2005) 1175-1181.
27. R. Saito, T. Sakai, I. Sato, Y. Sano, H. Oshitani, M. Sato, H. Suzuki, Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2, J. Clin. Microbiol. 41 (2003) 2164-2165.
28. Y. Wu, B. Canturk, H. Jo, C. Ma, E. Gianti, G. Fiorin, L.H. Pinto, R.A. Lamb, M.L. Klein, J. Wang, W.F. DeGrado, Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel, J. Am. Chem. Soc. 136 (2014) 17987-17995.
29. M. Rey-Carrizo, E. Torres, C. Ma, M. Barniol-Xicota, J. Wang, Y. Wu, L. Naesens, W.F. DeGrado, R.A. Lamb, L.H. Pinto, S. Vázquez, Azatetracyclo[ 5.2.1.15,8.01,5] undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant, J. Med. Chem. 56 (2013) 9265-9274.
30. M. Rey-Carrizo, M. Barniol-Xicota, C. Ma, M. Frigolé-Vivas, E. Torres, L. Naesens, S. Llabrés, J. Juárez-Jiménez, F.J. Luque, W.F. DeGrado, R.A. Lamb, L.H. Pinto, S. Vázquez, Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus, J. Med. Chem. 57 (2014) 5738-5747.
31. P. Camps, M.D. Duque, S. Vázquez, L. Naesens, E. De Clercq, F.X. Sureda, M. López-Querol, A. Camins, M. Pallás, S.R. Prathalingam, J.M. Kelly, V. Romero, D. Ivorra, D. Cortés, Synthesis and pharmacological evaluation of several ringcontracted amantadine analogs, Bioorg. Med. Chem. 16 (2008) 9925-9936.
32. M.D. Duque, C. Ma, E. Torres, J. Wang, L. Naesens, J. Juárez-Jiménez, P. Camps, F.J. Luque, W.F. DeGrado, R.A. Lamb, L.H. Pinto, S. Vázquez, Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus, J. Med. Chem. 54 (2011) 2646-2657.
33. E. Torres, R. Fernández, S. Miquet, M. Font-Bardia, E. Vanderlinden, L. Naesens, S. Vázquez, Synthesis and anti-influenza A virus activity of 2,2-dialkylamantadines and related compounds, ACS Med. Chem. Lett. 3 (2012) 1065-1069.
34. E. Torres, M.D. Duque, E. Vanderlinden, C. Ma, L.H. Pinto, P. Camps, M. Froeyen, S. Vázquez, L. Naesens, Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds, Antivir. Res. 99 (2013) 281-291.
35. M. Abou-Gharbia, U.R. Patel, M.B. Webb, J.A. Moyer, T.H. Andree, E.A. Muth, Polycyclic aryl-and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies, J. Med. Chem. 31 (1988) 1382-1392.
36. A. Srikrishna, Synthesis of hexacyclo[6.5.1.02,7.03,11.04,9.010,14]tetradeca-5,12-diene, Synth. Commun. 20 (1990) 279-284.
37. M.A. Forman, C. Moran, J.P. Herres, J. Stairs, E. Chopko, A. Pozzessere, M. Kerrigan, C. Kelly, L. Lowchyj, K. Salandria, A. Gallo, E. Loutzenhiser, Generation and reactions of pentacyclo[4.3.0.02,4.03,8.05,7]non-4-ene, J. Org. Chem. 72 (2007) 2996-3005.
38. G.A. Russell, G.W. Holland, K. Chang, G.K. Robert, C.S.C. Chung, K. Stanley, K. Schmitt, R. Blankespoor, Y. Kosugi, Aliphatic semidiones. XXV. Bicyclo[n.2.1] alkane-2,3-semidiones, J. Am. Chem. Soc. 96 (1974) 7237-7248.
39. The resulting crystal structure has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number CCDC 1049773.
40. S.D. Cady, K. Schmidt-Rohr, J. Wang, C.S. Soto, W.F. DeGrado, M. Hong, Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers, Nature 463 (2010) 689-692.
41. C. Hansch, A. Leo, D. Hoekman, Exploring QSAR: Hydrophobic, Electronic and Steric Constants, American Chemical Society, Washington, DC, 1995.
42. C. Curutchet, M. Orozco, F.J. Luque, Solvation in octanol: parametrization of the continuum MST model, J. Comput. Chem. 22 (2001) 1180-1193.
43. A. Leo, D. Hoekman, Calculating logP(oct) with no missing fragments; the problem of estimating new interaction parameters, Perspect. Drug Discov. Des. 18 (2000) 19-38.
44. A. Stevaert, R. Dallocchio, A. Dessì, N. Pala, D. Rogolino, M. Sechi, L. Naesens, Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease, J. Virol. 87 (2013) 10524-10538.
45. S. Gazzarrini, M. Kang, A. Abenavoli, G. Romani, G. Olivari, D. Gaslini, G. Ferrara, J.L. Van Etten, M. Kreim, S.M. Kast, G. Thiel, A. Moroni, Chlorella virus ATCV-1 encodes a functional potassium channel of 82 amino acids, Biochem.. J. 420 (2009) 295-303.
46. V. Balannik, R.A. Lamb, L.H. Pinto, The oligomeric state of the active BM2 ion channel protein of influenza B virus, J. Biol. Chem. 283 (2008) 4895-4904.
47. E. Vanderlinden, F. Göktas, Z. Cesur, M. Froeyen, M.L. Reed, C.J. Russell, N. Cesur, L. Naesens, Novel inhibitors of influenza virus fusion: structureactivity relationship and interaction with the viral hemagglutinin, J. Virol. 84 (2010) 4277-4288.
48. M. Sharma, M. Yi, H. Dong, H. Qin, E. Peterson, D.D. Busath, H.X. Zhou, T.A. Cross, Insight into the mechanism of the influenza A proton channel from a structure in a lipid bilayer, Science 330 (2010) 509-512.
49. M.A. Lomize, A.L. Lomize, I.D. Pogozheva, H.I. Mosberg, OPM: orientations of proteins in membranes database, Bioinformatics 22 (2006) 623-625.
50. R. Acharya, V. Carnevale, G. Florin, B.G. Levine, A.L. Polishchuk, V. Balannik, I. Samish, R.A. Lamb, L.H. Pinto, W.F. DeGrado, M.L. Klein, Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 15075-15080.
51. Marvin (2009). ChemAxon (http://www.chemaxon.com).
52. S. Jo, T. Kim, V.G. Iyer, Im W. CHARMM-GUI: a web-based Graphical user interface for CHARMM, J. Comput. Chem. 29 (2008) 1859-1865.
53. P. Mark, L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, J. Phys. Chem. A 105 (2001) 9954-9960.
54. V. Hornak, R. Abel, A. Okur, B. Strockbine, A. Roitberg, C. Simmerling, Comparison of multiple Amber force fields and development of improved protein backbone parameters, Proteins 65 (2006) 712-725.
55. J.M. Wang, R.M.Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and testing of a general amber force field, J. Comput. Chem. 26 (2005) 1157-1174.
56. D.A. Case, T.A. Darden, T.E. Cheatham III, C.L. Simmerling, J. Wang, R.E. Duke, R. Luo, R.C. Walker, W. Zhang, K.M. Merz, B. Roberts, S. Hayik, A. Roitberg, G. Seabra, J. Swails, A.W. Goetz, I. Kolossvary, K.F. Wong, F. Paesani, J. Vanicek, R.M. Wolf, J. Liu, X. Wu, S.R. Brozell, T. Steinbrecher, H. Gohlke, Q. Cai, X. Ye, J. Wang, M.-J. Hsieh, G. Cui, D.R. Roe, D.H. Mathews, M.G. Seetin, R. Salomon-Ferrer, C. Sagui, V. Babin, T. Luchko, S. Gusarov, A. Kovalenko, P.A. Kollman, AMBER 12, University of California, San Francisco, 2012.
57. C.J. Dickson, L. Rosso, R.M. Betz, R.C. Walker, I.R. Gould, GAFFlipid: a General Amber Force Field for the accurate molecular dynamics simulation of phospholipid, Soft Matter 8 (2012) 9617-9627.
58. I.S. Joung, T.E. Cheatham, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations, J. Phys. Chem. B 112 (2008) 9020-9041.
59. M. Kolár, J. Fanfrlík, M. Lepsík, F. Forti, F.J. Luque, P. Hobza, Assessing the accuracy and performance of implicit solvent models for drug molecules: conformational ensemble approaches, J. Phys. Chem. B 117 (2013) 5950-5962.
60. M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery Jr., J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J.M. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, Ö. Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. Fox, Gaussian 09, Revision B.01, Gaussian 09, Revis. B.01, Gaussian, Inc, 2009. Wallingford CT.
61. BioLoom 5.0 BioByte Co., Claremont, CA, USA. http://www.biobyte.com